Rachelle L. Dillon
Winnipeg, MB, Canada
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 8 publications
US Clinical Practice Patterns of Intravesical Chemotherapy for Bacillus Calmette-Guérin-Unresponsive and Bacillus Calmette-Guérin-Exposed Nonmuscle-Invasive Bladder Cancer.
Journal: Urology practice
Published: October 31, 2023
In vivo evidence supporting a metastasis suppressor role for Stard13 (Dlc2) in ErbB2 (Neu) oncogene induced mouse mammary tumors.
Journal: Genes, chromosomes & cancer
Published: September 08, 2017
DeBouganin Diabody Fusion Protein Overcomes Drug Resistance to ADCs Comprised of Anti-Microtubule Agents.
Journal: Molecules (Basel, Switzerland)
Published: October 15, 2016
Dlc1 interaction with non-muscle myosin heavy chain II-A (Myh9) and Rac1 activation.
Journal: Biology open
Published: March 16, 2016
Trastuzumab-deBouganin Conjugate Overcomes Multiple Mechanisms of T-DM1 Drug Resistance.
Journal: Journal of immunotherapy (Hagerstown, Md. : 1997)
Published: March 04, 2016
Human Leukocyte Antigen-Presented Macrophage Migration Inhibitory Factor Is a Surface Biomarker and Potential Therapeutic Target for Ovarian Cancer.
Journal: Molecular cancer therapeutics
Published: August 11, 2015
The Deleted in Liver Cancer 1 (Dlc1) tumor suppressor is haploinsufficient for mammary gland development and epithelial cell polarity.
Journal: BMC cancer
Published: February 03, 2015
Showing 1-8 of 8
Last Updated: 09/26/2026